Perspectives in mammalian IGFBP-3 biology: Local vs. systemic action

American Journal of Physiology - Cell Physiology

Volumn 296, Issue 5, 2009, Pages

  Yamada, Paulette M ^a   Lee, Kuk Wha ^a  

^a MATTEL CHILDREN S HOSPITAL   (United States)

Author keywords

Insulin like growth factor; Insulin like growth factor binding protein 3; Nonsuppressible insulin like activity

Indexed keywords

ANDROGEN; APIGENIN; CALCITRIOL; FULVESTRANT; GEFITINIB; HUMANIN; INTERLEUKIN 1BETA; MONOCLONAL ANTIBODY; NUCLEAR FACTOR Y; POLYPHENOL; PROSTATE SPECIFIC ANTIGEN; PROTEIN TYROSINE KINASE INHIBITOR; RECOMBINANT PROTEIN; RETINOIC ACID; RETINOID X RECEPTOR ALPHA; SILIBININ; SOMATOMEDIN; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN RECEPTOR ANTIBODY; TAMOXIFEN; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

CANCER INHIBITION; CELL PROLIFERATION; CLINICAL TRIAL; DRUG ACTIVITY; DRUG POTENTIATION; ERECTILE DYSFUNCTION; GENETIC TRANSCRIPTION; GLUCOSE TRANSPORT; HUMAN; LUNG NON SMALL CELL CANCER; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN DEGRADATION; PROTEIN GLYCOSYLATION; PROTEIN METHYLATION; PROTEIN PROCESSING; PROTEIN STRUCTURE; PROTEIN SYNTHESIS; REVIEW; TUMOR RECURRENCE; UBIQUITINATION;

ANIMALS; AUTOCRINE COMMUNICATION; CELL DIVISION; ENDOCRINE SYSTEM; HUMANS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 3; MAMMALS; NEOPLASMS; PARACRINE COMMUNICATION;

MAMMALIA;

EID: 66149158452     PISSN: 03636143     EISSN: 15221563     Source Type: Journal    
DOI: 10.1152/ajpcell.00598.2008     Document Type: Review

References (265)

1. Abdelbaky TM, Brock GB, Huynh H. Improvement of erectile function in diabetic rats by insulin: possible role of the insulin-like growth factor system. Endocrinology 139: 3143-3147, 1998.
2. Adamo ML, Shao ZM, Lanau F, Chen JC, Clemmons DR, Roberts CT Jr, LeRoith D, and Fontana JA. Insulin-like growth factor-I (IGF-I) and retinoic acid modulation of IGF-binding proteins (IGFBPs): IGFBP-2, -3, and -4 gene expression and protein secretion in a breast cancer cell line. Endocrinology 131: 1858-1866, 1992.
3. Adhami VM, Siddiqui IA, Ahmad N, Gupta S, Mukhtar H. Oral consumption of green tea polyphenols inhibits insulin-like growth factor- I-induced signaling in an autochthonous mouse model of prostate cancer. Cancer Res 64: 8715-8722, 2004.
4. Agarwal C, Lambert A, Chandraratna RA, Rorke EA, Eckert RL. Vitamin D regulates human ectocervical epithelial cell proliferation and insulin-like growth factor-binding protein-3 level. Biol Reprod 60: 567-572, 1999.
5. Ahlsen M, Carlsson-Skwirut C, Jonsson AP, Cederlund E, Bergman T, Bang P. A 30-kDa fragment of insulin-like growth factor (IGF) binding protein-3 in human pregnancy serum with strongly reduced IGF-I binding. Cell Mol Life Sci 64: 1870-1880, 2007.
6. Ali O, Cohen P, Lee KW. Epidemiology and biology of insulin-like growth factor binding protein-3 (IGFBP-3) as an anti-cancer molecule. Horm Metab Res 35: 726-733, 2003.
7. Andreatta-Van Leyen S, Hembree JR, Eckert RL. Regulation of insulin-like growth factor 1 binding protein 3 levels by epidermal growth factor and retinoic acid in cervical epithelial cells. J Cell Physiol 160: 265-274, 1994.
8. Anwar A, Zahid AA, Scheidegger KJ, Brink M, Delafontaine P. Tumor necrosis factor-alpha regulates insulin-like growth factor-1 and insulin-like growth factor binding protein-3 expression in vascular smooth muscle. Circulation 105: 1220-1225, 2002.
9. Arnold JT, Le H, McFann KK, Blackman MR. Comparative effects of DHEA vs. testosterone, dihydrotestosterone, and estradiol on proliferation and gene expression in human LNCaP prostate cancer cells. Am J Physiol Endocrinol Metab 288: E573-E584, 2005.
10. Atadja P, Wong H, Garkavtsev I, Veillette C, Riabowol K. Increased activity of p53 in senescing fibroblasts. Proc Natl Acad Sci USA 92: 8348-8352, 1995.
11. Bail HJ, Kolbeck S, Lindner T, Dahne M, Weiler A, Windhagen HJ, Raun K, Skjaerbaek C, Flyvbjerg A, Orskov H, Haas NP, Raschke MJ. The effect of growth hormone on insulin-like growth factor I and bone metabolism in distraction osteogenesis. Growth Horm IGF Res 11: 314-323, 2001.
12. Bang P, Brismar K, Rosenfeld RG. Increased proteolysis of insulin-like growth factor-binding protein-3 (IGFBP-3) in noninsulin-dependent diabetes mellitus serum, with elevation of a 29-kilodalton (kDa) glycosylated IGFBP-3 fragment contained in the approximately 130- to 150-kDa ternary complex. J Clin Endocrinol Metab 78: 1119-1127, 1994.
13. Bang P, Fielder PJ. Human pregnancy serum contains at least two distinct proteolytic activities with the ability to degrade insulin-like growth factor binding protein-3. Endocrinology 138: 3912-3917, 1997.
14. Bang P, Nygren J, Carlsson-Skwirut C, Thorell A, Ljungqvist O. Postoperative induction of insulin-like growth factor binding protein-3 proteolytic activity: relation to insulin and insulin sensitivity. J Clin Endocrinol Metab 83: 2509-2515, 1998.
15. Baron AD, Brechtel-Hook G, Johnson A, Hardin D. Skeletal muscle blood flow. A possible link between insulin resistance and blood pressure. Hypertension 21: 129-135, 1993.
16. Barreca A, Artini PG, Cesarone A, Arvigo M, D'Ambrogio G, Genazzani AR, Giordano G, Minuto F. Interrelationships between follicle stimulating hormone and the growth hormone-insulin-like growth factor-IGF-binding proteins axes in human granulosa cells in culture. J Endocrinol Invest 19: 35-42, 1996.
17. Baxter RC, Martin JL, Beniac VA. High molecular weight insulin-like growth factor binding protein complex. Purification and properties of the acid-labile subunit from human serum. J Biol Chem 264: 11843-11848, 1989.
18. Blum WF, Ranke MB. Insulin-like growth factor binding proteins (IGFBPs) with special reference to IGFBP-3. Acta Paediatr Scand Suppl 367: 55-62, 1990.
19. Blum WF, Ranke MB, Kietzmann K, Gauggel E, Zeisel HJ, Bierich JR. A specific radioimmunoassay for the growth hormone (GH)-dependent somatomedin-binding protein: its use for diagnosis of GH deficiency. J Clin Endocrinol Metab 70: 1292-1298, 1990.
20. Boffa LC, Gruss RJ, Allfrey VG. Manifold effects of sodium butyrate on nuclear function. Selective and reversible inhibition of phosphorylation of histones H1 and H2A and impaired methylation of lysine and arginine residues in nuclear protein fractions. J Biol Chem 256: 9612-9621, 1981.
21. Booth BA, Boes M, Andress DL, Dake BL, Kiefer MC, Maack C, Linhardt RJ, Bar K, Caldwell EE, Weiler J, and et al. IGFBP-3 and IGFBP-5 association with endothelial cells: role of C-terminal heparin binding domain. Growth Regul 5: 1-17, 1995.
22. Boyle BJ, Zhao XY, Cohen P, Feldman D. Insulin-like growth factor binding protein-3 mediates 1 alpha,25-dihydroxyvitamin d(3) growth inhibition in the LNCaP prostate cancer cell line through p21/WAF1. J Urol 165: 1319-1324, 2001.
23. Bramani S, Song H, Beattie J, Tonner E, Flint DJ, Allan GJ. Amino acids within the extracellular matrix (ECM) binding region (201-218) of rat insulin-like growth factor binding protein (IGFBP)-5 are important determinants in binding IGF-I. J Mol Endocrinol 23: 117-123, 1999.
24. Buckbinder L, Talbott R, Seizinger BR, Kley N. Gene regulation by temperature-sensitive p53 mutants: identification of p53 response genes. Proc Natl Acad Sci USA 91: 10640-10644, 1994.
25. Buckbinder L, Talbott R, Velasco-Miguel S, Takenaka I, Faha B, Seizinger BR, Kley N. Induction of the growth inhibitor IGF-binding protein 3 by p53. Nature 377: 646-649, 1995.
26. Buckway CK, Wilson EM, Ahlsen M, Bang P, Oh Y, Rosenfeld RG. Mutation of three critical amino acids of the N-terminal domain of IGF-binding protein-3 essential for high affinity IGF binding. J Clin Endocrinol Metab 86: 4943-4950, 2001.
27. Burrows C, Holly JM, Laurence NJ, Vernon EG, Carter JV, Clark MA, McIntosh J, McCaig C, Winters ZE, Perks CM. Insulin-like growth factor binding protein 3 has opposing actions on malignant and nonmalignant breast epithelial cells that are each reversible and dependent upon cholesterol-stabilized integrin receptor complexes. Endocrinology 147: 3484-3500, 2006.
28. Butt AJ, Fraley KA, Firth SM, Baxter RC. IGF-binding protein-3- induced growth inhibition and apoptosis do not require cell surface binding and nuclear translocation in human breast cancer cells. Endocrinology 143: 2693-2699, 2002.
29. Campbell PG, Durham SK, Hayes JD, Suwanichkul A, Powell DR. Insulin-like growth factor-binding protein-3 binds fibrinogen and fibrin. J Biol Chem 274: 30215-30221, 1999.
30. Campbell PG, Durham SK, Suwanichkul A, Hayes JD, Powell DR. Plasminogen binds the heparin-binding domain of insulin-like growth factor-binding protein-3. Am J Physiol Endocrinol Metab 275: E321-E331, 1998.
31. Campbell PG, Novak JF, Yanosick TB, McMaster JH. Involvement of the plasmin system in dissociation of the insulin-like growth factor-binding protein complex. Endocrinology 130: 1401-1412, 1992.
32. Carducci MA, Nelson JB, Chan-Tack KM, Ayyagari SR, Sweatt WH, Campbell PA, Nelson WG, Simons JW. Phenylbutyrate induces apoptosis in human prostate cancer and is more potent than phenylacetate. Clin Cancer Res 2: 379-387, 1996.
33. Carr JM, Owens JA, Baudinette RV, Wallace JC. Analysis of insulin-like growth factor binding proteins in the tammar wallaby, Macropus eugenii. Gen Comp Endocrinol 99: 50-59, 1995.
34. Chan SS, Schedlich LJ, Twigg SM, Baxter RC. Inhibition of adipocyte differentiation by insulin-like growth factor binding protein-3. Am J Physiol Endocrinol Metab 296: E654-E663, 2009.
35. Chan SS, Twigg SM, Firth SM, Baxter RC. Insulin-like growth factor binding protein-3 leads to insulin resistance in adipocytes. J Clin Endocrinol Metab 90: 6588-6595, 2005.
36. Chang KH, Chan-Ling T, McFarland EL, Afzal A, Pan H, Baxter LC, Shaw LC, Caballero S, Sengupta N, Li Calzi S, Sullivan SM, Grant MB. IGF binding protein-3 regulates hematopoietic stem cell and endothelial precursor cell function during vascular development. Proc Natl Acad Sci USA 104: 10595-10600, 2007.
37. Chang YS, Kong G, Sun S, Liu D, El-Naggar AK, Khuri FR, Hong WK, Lee HY. Clinical significance of insulin-like growth factor-binding protein-3 expression in stage I non-small cell lung cancer. Clin Cancer Res 8: 3796-3802, 2002.
38. Chang YS, Wang L, Liu D, Mao L, Hong WK, Khuri FR, Lee HY. Correlation between insulin-like growth factor-binding protein-3 promoter methylation and prognosis of patients with stage I non-small cell lung cancer. Clin Cancer Res 8: 3669-3675, 2002.
39. Chen D, Li M, Luo J, Gu W. Direct interactions between HIF-1 alpha and Mdm2 modulate p53 function. J Biol Chem 278: 13595-13598, 2003.
40. Chen X, Ferry RJ Jr. Novel actions of IGFBP-3 on intracellular signaling pathways of insulin-secreting cells. Growth Horm IGF Res 16: 41-48, 2006.
41. Clemmons DR, Thissen JP, Maes M, Ketelslegers JM, Underwood LE. Insulin-like growth factor-I (IGF-I) infusion into hypophysectomized or protein-deprived rats induces specific IGF-binding proteins in serum. Endocrinology 125: 2967-2972, 1989.
42. Cobb LJ, Liu B, Lee KW, Cohen P. Phosphorylation by DNA-dependent protein kinase is critical for apoptosis induction by insulin-like growth factor binding protein-3. Cancer Res 66: 10878-10884, 2006.
43. Cohen P, Graves HC, Peehl DM, Kamarei M, Giudice LC, Rosenfeld RG. Prostate-specific antigen (PSA) is an insulin-like growth factor binding protein-3 protease found in seminal plasma. J Clin Endocrinol Metab 75: 1046-1053, 1992.
44. Cohen P, Peehl DM, Graves HC, Rosenfeld RG. Biological effects of prostate specific antigen as an insulin-like growth factor binding protein- 3 protease. J Endocrinol 142: 407-415, 1994.
45. Colon E, Svechnikov KV, Carlsson-Skwirut C, Bang P, Soder O. Stimulation of steroidogenesis in immature rat Leydig cells evoked by interleukin-1alpha is potentiated by growth hormone and insulin-like growth factors. Endocrinology 146: 221-230, 2005.
46. Colston KW, Perks CM, Xie SP, Holly JM. Growth inhibition of both MCF-7 and Hs578T human breast cancer cell lines by vitamin D analogues is associated with increased expression of insulin-like growth factor binding protein-3. J Mol Endocrinol 20: 157-162, 1998.
47. Conover CA, De Leon DD. Acid-activated insulin-like growth factor-binding protein-3 proteolysis in normal and transformed cells. Role of cathepsin D. J Biol Chem 269: 7076-7080, 1994.
48. Conover CA, Powell DR. Insulin-like growth factor (IGF)-binding protein-3 blocks IGF-I-induced receptor down-regulation and cell desensitization in cultured bovine fibroblasts. Endocrinology 129: 710-716, 1991.
49. Coverley JA, Martin JL, Baxter RC. The effect of phosphorylation by casein kinase 2 on the activity of insulin-like growth factor-binding protein-3. Endocrinology 141: 564-570, 2000.
50. Cwyfan Hughes S, Mason HD, Franks S, Holly JM. Modulation of the insulin-like growth factor-binding proteins by follicle size in the human ovary. J Endocrinol 154: 35-43, 1997.
51. Daughaday WH, Hall K, Raben MS, Salmon WD Jr, van den Brande JL, and van Wyk JJ. Somatomedin: proposed designation for sulphation factor. Nature 235: 107, 1972.
52. Davenport ML, Isley WL, Pucilowska JB, Pemberton LB, Lyman B, Underwood LE, Clemmons DR. Insulin-like growth factor-binding protein-3 proteolysis is induced after elective surgery. J Clin Endocrinol Metab 75: 590-595, 1992.
53. Davies SC, Wass JA, Ross RJ, Cotterill AM, Buchanan CR, Coulson VJ, Holly JM. The induction of a specific protease for insulin-like growth factor binding protein-3 in the circulation during severe illness. J Endocrinol 130: 469-473, 1991.
54. Dawson MI, Hobbs PD, Peterson VJ, Leid M, Lange CW, Feng KC, Chen G, Gu J, Li H, Kolluri SK, Zhang X, Zhang Y, Fontana JA. Apoptosis induction in cancer cells by a novel analogue of 6-[3-(1- adamantyl)-4-hydroxyphenyl]-2- naphthalenecarboxylic acid lacking retinoid receptor transcriptional activation activity. Cancer Res 61: 4723-4730, 2001.
55. De Benedetti F, Alonzi T, Moretta A, Lazzaro D, Costa P, Poli V, Martini A, Ciliberto G, Fattori E. Interleukin 6 causes growth impairment in transgenic mice through a decrease in insulin-like growth factor-I. A model for stunted growth in children with chronic inflammation. J Clin Invest 99: 643-650, 1997.
56. De Benedetti F, Meazza C, Oliveri M, Pignatti P, Vivarelli M, Alonzi T, Fattori E, Garrone S, Barreca A, Martini A. Effect of IL-6 on IGF binding protein-3: a study in IL-6 transgenic mice and in patients with systemic juvenile idiopathic arthritis. Endocrinology 142: 4818-4826, 2001.
57. Delafontaine P, Lou H, Alexander RW. Regulation of insulin-like growth factor I messenger RNA levels in vascular smooth muscle cells. Hypertension 18: 742-747, 1991.
58. Delaney CA, Pavlovic D, Hoorens A, Pipeleers DG, Eizirik DL. Cytokines induce deoxyribonucleic acid strand breaks and apoptosis in human pancreatic islet cells. Endocrinology 138: 2610-2614, 1997.
59. Dinarello CA, Savage N. Interleukin-1 and its receptor. Crit Rev Immunol 9: 1-20, 1989.
60. Dobson ME, Ingram VM. In vitro transcription of chromatin containing histones hyperacetylated in vivo. Nucleic Acids Res 8: 4201-4219, 1980.
61. Duan C, Xu Q. Roles of insulin-like growth factor (IGF) binding proteins in regulating IGF actions. Gen Comp Endocrinol 142: 44-52, 2005.
62. el-Deiry WS, Kern SE, Pietenpol JA, Kinzler KW, Vogelstein B. Definition of a consensus binding site for p53. Nat Genet 1: 45-49, 1992.
63. Engelman JA. The role of phosphoinositide 3-kinase pathway inhibitors in the treatment of lung cancer. Clin Cancer Res 13: s4637-4640, 2007.
64. Engelman JA, Janne PA. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res 14: 2895-2899, 2008.
65. Fanayan S, Firth SM, Baxter RC. Signaling through the Smad pathway by insulin-like growth factor-binding protein-3 in breast cancer cells. Relationship to transforming growth factor-beta 1 signaling. J Biol Chem 277: 7255-7261, 2002.
66. Fanayan S, Firth SM, Butt AJ, Baxter RC. Growth inhibition by insulin-like growth factor-binding protein-3 in T47D breast cancer cells requires transforming growth factor-beta (TGF-beta) and the type II TGF-beta receptor. J Biol Chem 275: 39146-39151, 2000.
67. Feldser D, Agani F, Iyer NV, Pak B, Ferreira G, Semenza GL. Reciprocal positive regulation of hypoxia-inducible factor 1alpha and insulin-like growth factor 2. Cancer Res 59: 3915-3918, 1999.
68. Fernihough JK, Billingham ME, Cwyfan-Hughes S, Holly JM. Local disruption of the insulin-like growth factor system in the arthritic joint. Arthritis Rheum 39: 1556-1565, 1996.
69. Fernihough JK, Innes JF, Billingham ME, Holly JM. Changes in the local regulation of insulin-like growth factors I and II and insulin-like growth factor-binding proteins in osteoarthritis of the canine stifle joint secondary to cruciate ligament rupture. Vet Surg 32: 313-323, 2003.
70. Firth SM, Baxter RC. Cellular actions of the insulin-like growth factor binding proteins. Endocrinol Rev 23: 824-854, 2002.
71. Firth SM, Baxter RC. Characterisation of recombinant glycosylation variants of insulin-like growth factor binding protein-3. J Endocrinol 160: 379-387, 1999.
72. Firth SM, Baxter RC. The role of glycosylation in the action of IGFBP-3. Prog Growth Factor Res 6: 223-229, 1995.
73. Firth SM, Ganeshprasad U, Baxter RC. Structural determinants of ligand and cell surface binding of insulin-like growth factor-binding protein-3. J Biol Chem 273: 2631-2638, 1998.
74. Fontana JA, Burrows-Mezu A, Clemmons DR, LeRoith D. Retinoid modulation of insulin-like growth factor-binding proteins and inhibition of breast carcinoma proliferation. Endocrinology 128: 1115-1122, 1991.
75. Fortier LA, Kornatowski MA, Mohammed HO, Jordan MT, O'Cain LC, Stevens WB. Age-related changes in serum insulin-like growth factor-I, insulin-like growth factor-I binding protein-3 and articular cartilage structure in Thoroughbred horses. Equine Vet J 37: 37-42, 2005.
76. Foulstone EJ, Savage PB, Crown AL, Holly JM, Stewart CE. Role of insulin-like growth factor binding protein-3 (IGFBP-3) in the differentiation of primary human adult skeletal myoblasts. J Cell Physiol 195: 70-79, 2003.
77. Fowlkes JL, Serra DM. Characterization of glycosaminoglycan-binding domains present in insulin-like growth factor-binding protein-3. J Biol Chem 271: 14676-14679, 1996.
78. Fowlkes JL, Suzuki K, Nagase H, Thrailkill KM. Proteolysis of insulin-like growth factor binding protein-3 during rat pregnancy: a role for matrix metalloproteinases. Endocrinology 135: 2810-2813, 1994.
79. Franklin SL, Ferry RJ Jr, Cohen P. Rapid insulin-like growth factor (IGF)-independent effects of IGF binding protein-3 on endothelial cell survival. J Clin Endocrinol Metab 88: 900-907, 2003.
80. Freeman SM, Whartenby KA. The role of the mitogen-activated protein kinase cellular signaling pathway in tumor cell survival and apoptosis. Drug News Perspect 17: 237-242, 2004.
81. Froesch ER, Zapf J, Audhya TK, Ben-Porath E, Segen BJ, Gibson KD. Nonsuppressible insulin-like activity and thyroid hormones: major pituitary-dependent sulfation factors for chick embryo cartilage. Proc Natl Acad Sci USA 73: 2904-2908, 1976.
82. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, Nishiwaki Y, Vansteenkiste J, Kudoh S, Rischin D, Eek R, Horai T, Noda K, Takata I, Smit E, Averbuch S, Macleod A, Feyereislova A, Dong RP, Baselga J. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 21: 2237-2246, 2003.
83. Funaki M, Randhawa P, Janmey PA. Separation of insulin signaling into distinct GLUT4 translocation and activation steps. Mol Cell Biol 24: 7567-7577, 2004.
84. Galanis M, Firth SM, Bond J, Nathanielsz A, Kortt AA, Hudson PJ, Baxter RC. Ligand-binding characteristics of recombinant amino- and carboxyl-terminal fragments of human insulin-like growth factor-binding protein-3. J Endocrinol 169: 123-133, 2001.
85. Galbiati F, Razani B, Lisanti MP. Emerging themes in lipid rafts and caveolae. Cell 106: 403-411, 2001.
86. Gatford KL, Dalitz PA, Cock ML, Harding R, Owens JA. Acute ethanol exposure in pregnancy alters the insulin-like growth factor axis of fetal and maternal sheep. Am J Physiol Endocrinol Metab 292: E494-E500, 2007.
87. Gelmann EP. Molecular biology of the androgen receptor. J Clin Oncol 20: 3001-3015, 2002.
88. Gibson CA, Staley MD, Baumrucker CR. Identification of IGF binding proteins in bovine milk and the demonstration of IGFBP-3 synthesis and release by bovine mammary epithelial cells. J Anim Sci 77: 1547-1557, 1999.
89. Glasscock GF, Hein AN, Miller JA, Hintz RL, Rosenfeld RG. Effects of continuous infusion of insulin-like growth factor I and II, alone and in combination with thyroxine or growth hormone, on the neonatal hypophysectomized rat. Endocrinology 130: 203-210, 1992.
90. Goda N, Tenno T, Inomata K, Shirakawa M, Tanaka T, Hiroaki H. Intracellular protein delivery activity of peptides derived from insulinlike growth factor binding proteins 3 and 5. Exp Cell Res 314: 2352-2361, 2008.
91. Goldstein S, Moerman EJ, Jones RA, Baxter RC. Insulin-like growth factor binding protein 3 accumulates to high levels in culture medium of senescent and quiescent human fibroblasts. Proc Natl Acad Sci USA 88: 9680-9684, 1991.
92. Goossens K, Esquenet M, Swinnen JV, Manin M, Rombauts W, Verhoeven G. Androgens decrease and retinoids increase the expression of insulin-like growth factor-binding protein-3 in LNcaP prostatic adenocarcinoma cells. Mol Cell Endocrinol 155: 9-18, 1999.
93. Granata R, Trovato L, Lupia E, Sala G, Settanni F, Camussi G, Ghidoni R, Ghigo E. Insulin-like growth factor binding protein-3 induces angiogenesis through IGF-I- and SphK1-dependent mechanisms. J Thromb Haemost 5: 835-845, 2007.
94. Grimberg A, Cohen P. Role of insulin-like growth factors and their binding proteins in growth control and carcinogenesis. J Cell Physiol 183: 1-9, 2000.
95. Grimberg A, Coleman CM, Burns TF, Himelstein BP, Koch CJ, Cohen P, and El-Deiry WS. p53-Dependent and p53-independent induction of insulin-like growth factor binding protein-3 by deoxyribonucleic acid damage and hypoxia. J Clin Endocrinol Metab 90: 3568-3574, 2005.
96. Gucev ZS, Oh Y, Kelley KM, Labarta JI, Vorwerk P, Rosenfeld RG. Evidence for insulin-like growth factor (IGF)-independent transcriptional regulation of IGF binding protein-3 by growth hormone in SKHEP-1 human hepatocarcinoma cells. Endocrinology 138: 1464-1470, 1997.
97. Gucev ZS, Oh Y, Kelley KM, Rosenfeld RG. Insulin-like growth factor binding protein 3 mediates retinoic acid- and transforming growth factor beta2-induced growth inhibition in human breast cancer cells. Cancer Res 56: 1545-1550, 1996.
98. Guevara-Aguirre J, Vasconez O, Martinez V, Martinez AL, Rosenbloom AL, Diamond FB Jr, Gargosky SE, Nonoshita L, and Rosenfeld RG. A randomized, double blind, placebo-controlled trial on safety and efficacy of recombinant human insulin-like growth factor-I in children with growth hormone receptor deficiency. J Clin Endocrinol Metab 80: 1393-1398, 1995.
99. Gui Y, Murphy LJ. Insulin-like growth factor (IGF)-binding protein-3 (IGFBP-3) binds to fibronectin (FN): demonstration of IGF-I/IGFBP-3/fn ternary complexes in human plasma. J Clin Endocrinol Metab 86: 2104-2110, 2001.
100. Gui Y, Murphy LJ. Interaction of insulin-like growth factor binding protein-3 with latent transforming growth factor-beta binding protein-1. Mol Cell Biochem 250: 189-195, 2003.
101. Guix M, Faber AC, Wang SE, Olivares MG, Song Y, Qu S, Rinehart C, Seidel B, Yee D, Arteaga CL, Engelman JA. Acquired resistance to EGFR tyrosine kinase inhibitors in cancer cells is mediated by loss of IGF-binding proteins. J Clin Invest 118: 2609-2619, 2008.
102. Guler HP, Zapf J, Schmid C, Froesch ER. Insulin-like growth factors I and II in healthy man. Estimations of half-lives and production rates. Acta Endocrinol 121: 753-758, 1989.
103. Han GR, Dohi DF, Lee HY, Rajah R, Walsh GL, Hong WK, Cohen P, Kurie JM. All-trans-retinoic acid increases transforming growth factor-beta2 and insulin-like growth factor binding protein-3 expression through a retinoic acid receptor-alpha-dependent signaling pathway. J Biol Chem 272: 13711-13716, 1997.
104. Hanafusa T, Yumoto Y, Nouso K, Nakatsukasa H, Onishi T, Fujikawa T, Taniyama M, Nakamura S, Uemura M, Takuma Y, Yumoto E, Higashi T, Tsuji T. Reduced expression of insulin-like growth factor binding protein-3 and its promoter hypermethylation in human hepatocellular carcinoma. Cancer Lett 176: 149-158, 2002.
105. Hardouin S, Gourmelen M, Noguiez P, Seurin D, Roghani M, Le Bouc Y, Povoa G, Merimee TJ, Hossenlopp P, Binoux M. Molecular forms of serum insulin-like growth factor (IGF)-binding proteins in man: relationships with growth hormone and IGFs and physiological significance. J Clin Endocrinol Metab 69: 1291-1301, 1989.
106. Harms KL, Chen X. The C terminus of p53 family proteins is a cell fate determinant. Mol Cell Biol 25: 2014-2030, 2005.
107. Hasegawa Y, Hasegawa T, Aso T, Kotoh S, Tsuchiya Y, Nose O, Ohyama Y, Araki K, Tanaka T, Saisyo S, and et al. Comparison between insulin-like growth factor-I (IGF-I) and IGF binding protein-3 (IGFBP-3) measurement in the diagnosis of growth hormone deficiency. Endocr J 40: 185-190, 1993.
108. Hashimoto Y, Tsuji O, Niikura T, Yamagishi Y, Ishizaka M, Kawasumi M, Chiba T, Kanekura K, Yamada M, Tsukamoto E, Kouyama K, Terashita K, Aiso S, Lin A, Nishimoto I. Involvement of c-Jun N-terminal kinase in amyloid precursor protein-mediated neuronal cell death. J Neurochem 84: 864-877, 2003.
109. Hembree JR, Agarwal C, Beard RL, Chandraratna RA, Eckert R. Retinoid X receptor-specific retinoids inhibit the ability of retinoic acid receptor-specific retinoids to increase the level of insulin-like growth factor binding protein-3 in human ectocervical epithelial cells. Cancer Res 56: 1794-1799, 1996.
110. Hershko A, Ciechanover A. The ubiquitin system. Annu Rev Biochem 67: 425-479, 1998.
111. Hoeck WG, Mukku VR. Identification of the major sites of phosphorylation in IGF binding protein-3. J Cell Biochem 56: 262-273, 1994.
112. Holmes WF, Soprano DR, Soprano KJ. Comparison of the mechanism of induction of apoptosis in ovarian carcinoma cells by the conformationally restricted synthetic retinoids CD437 and 4-HPR. J Cell Biochem 89: 262-278, 2003.
113. Honda M, Eriksson KS, Zhang S, Tanaka S, Lin L, Salehi A, Hesla PE, Maehlen J, Gaus SE, Yanagisawa M, Sakurai T, Taheri S, Tsuchiya K, Honda Y, Mignot E. IGFBP3 colocalizes with and regulates hypocretin (orexin). PLoS ONE 4: e4254, 2009.
114. Honegger B, Galic M, Kohler K, Wittwer F, Brogiolo W, Hafen E, Stocker H. Imp-L2, a putative homolog of vertebrate IGF-binding protein 7, counteracts insulin signaling in Drosophila and is essential for starvation resistance. J Biol 7: 10, 2008.
115. Hong J, Zhang G, Dong F, Rechler MM. Insulin-like growth factor (IGF)-binding protein-3 mutants that do not bind IGF-I or IGF-II stimulate apoptosis in human prostate cancer cells. J Biol Chem 277: 10489-10497, 2002.
116. Hossenlopp P, Segovia B, Lassarre C, Roghani M, Bredon M, Binoux M. Evidence of enzymatic degradation of insulin-like growth factor-binding proteins in the 150K complex during pregnancy. J Clin Endocrinol Metab 71: 797-805, 1990.
117. Huang SS, Leal SM, Chen CL, Liu IH, Huang JS. Identification of insulin receptor substrate proteins as key molecules for the TbetaR-V/ LRP-1-mediated growth inhibitory signaling cascade in epithelial and myeloid cells. FASEB J 18: 1719-1721, 2004.
118. Huang SS, Ling TY, Tseng WF, Huang YH, Tang FM, Leal SM, Huang JS. Cellular growth inhibition by IGFBP-3 and TGF-beta1 requires LRP-1. FASEB J 17: 2068-2081, 2003.
119. Hughes SC, Xu S, Fernihough J, Hampton A, Mason HD, Franks S, van der Stappen J, Donnelly MJ, Holly JM. Tissue IGFBP-3 proteolysis: contrasting pathophysiology to that in the circulation. Prog Growth Factor Res 6: 293-299, 1995.
120. Hung H, Pollak M. Regulation of IGFBP-3 expression in breast cancer cells and uterus by estradiol and antiestrogens: correlations with effects on proliferation: a review. Prog Growth Factor Res 6: 495-501, 1995.
121. Huynh H, Pollak M, Zhang JC. Regulation of insulin-like growth factor (IGF) II and IGF binding protein 3 autocrine loop in human PC-3 prostate cancer cells by vitamin D metabolite 1,25(OH)2D3 and its analog EB1089. Int J Oncol 13: 137-143, 1998.
122. Huynh H, Yang X, Pollak M. Estradiol and antiestrogens regulate a growth inhibitory insulin-like growth factor binding protein 3 autocrine loop in human breast cancer cells. J Biol Chem 271: 1016-1021, 1996.
123. Hwa V, Oh Y, Rosenfeld RG. Insulin-like growth factor binding protein-3 and -5 are regulated by transforming growth factor-beta and retinoic acid in the human prostate adenocarcinoma cell line PC-3. Endocrine 6: 235-242, 1997.
124. Iannuzzi L, Di Meo GP, Perucatti A, Schibler L, Incarnato D, Gallagher D, Eggen A, Ferretti L, Cribiu EP, Womack J. The river buffalo (Bubalus bubalis, 2n = 50) cytogenetic map: assignment of 64 loci by fluorescence in situ hybridization and R-banding. Cytogenet Genome Res 102: 65-75, 2003.
125. Ikonen M, Liu B, Hashimoto Y, Ma L, Lee KW, Niikura T, Nishimoto I, Cohen P. Interaction between the Alzheimer's survival peptide humanin and insulin-like growth factor-binding protein 3 regulates cell survival and apoptosis. Proc Natl Acad Sci USA 100: 13042-13047, 2003.
126. Issa JP. Methylation and prognosis: of molecular clocks and hypermethylator phenotypes. Clin Cancer Res 9: 2879-2881, 2003.
127. Jaques G, Noll K, Wegmann B, Witten S, Kogan E, Radulescu RT, Havemann K. Nuclear localization of insulin-like growth factor binding protein 3 in a lung cancer cell line. Endocrinology 138: 1767-1770, 1997.
128. Jonsson CK, Setchell BP, Martinelle N, Svechnikov K, Soder O. Endotoxin-induced interleukin 1 expression in testicular macrophages is accompanied by downregulation of the constitutive expression in Sertoli cells. Cytokine 14: 283-288, 2001.
129. Kalus W, Zweckstetter M, Renner C, Sanchez Y, Georgescu J, Grol M, Demuth D, Schumacher R, Dony C, Lang K, Holak TA. Structure of the IGF-binding domain of the insulin-like growth factor-binding protein-5 (IGFBP-5): implications for IGF and IGF-I receptor interactions. EMBO J 17: 6558-6572, 1998.
130. Kanety H, Karasik A, Klinger B, Silbergeld A, Laron Z. Long-term treatment of Laron type dwarfs with insulin-like growth factor-1 increases serum insulin-like growth factor-binding protein-3 in the absence of growth hormone activity. Acta Endocrinol 128: 144-149, 1993.
131. Kasper S, Sheppard PC, Yan Y, Pettigrew N, Borowsky AD, Prins GS, Dodd JG, Duckworth ML, Matusik RJ. Development, progression, and androgen-dependence of prostate tumors in probasin-large T antigen transgenic mice: a model for prostate cancer. Lab Invest 78: 319-333, 1998.
132. Kaufmann U, Zapf J, Torretti B, Froesch ER. Demonstration of a specific serum carrier protein of nonsuppressible insulin-like activity in vivo. J Clin Endocrinol Metab 44: 160-166, 1977.
133. Kim HS, Ali O, Shim M, Lee KW, Vuguin P, Muzumdar R, Barzilai N, Cohen P. Insulin-like growth factor binding protein-3 induces insulin resistance in adipocytes in vitro and in rats in vivo. Pediatr Res 61: 159-164, 2007.
134. Kim ST, Lim DS, Canman CE, Kastan MB. Substrate specificities and identification of putative substrates of ATM kinase family members. J Biol Chem 274: 37538-37543, 1999.
135. Knabbe C, Lippman ME, Wakefield LM, Flanders KC, Kasid A, Derynck R, Dickson RB. Evidence that transforming growth factor-beta is a hormonally regulated negative growth factor in human breast cancer cells. Cell 48: 417-428, 1987.
136. Kojic LD, Wiseman SM, Ghaidi F, Joshi B, Nedev H, Saragovi HU, Nabi IR. Raft-dependent endocytosis of autocrine motility factor/phosphoglucose isomerase: a potential drug delivery route for tumor cells. PLoS ONE 3: e3597, 2008.
137. Kojima S, Mulholland DJ, Ettinger S, Fazli L, Nelson CC, Gleave ME. Differential regulation of IGFBP-3 by the androgen receptor in the lineage-related androgen-dependent LNCaP and androgen-independent C4-2 prostate cancer models. Prostate 66: 971-986, 2006.
138. Kris MG, Natale RB, Herbst RS, Lynch TJ Jr, Prager D, Belani CP, Schiller JH, Kelly K, Spiridonidis H, Sandler A, Albain KS, Cella D, Wolf MK, Averbuch SD, Ochs JJ, and Kay AC. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290: 2149-2158, 2003.
139. Krishnan AV, Peehl DM, Feldman D. Inhibition of prostate cancer growth by vitamin D: Regulation of target gene expression. J Cell Biochem 88: 363-371, 2003.
140. Kruh J. Effects of sodium butyrate, a new pharmacological agent, on cells in culture. Mol Cell Biochem 42: 65-82, 1982.
141. Lalou C, Lassarre C, Binoux M. Isolation and characterization of proteolytic fragments of insulin-like growth factor-binding protein-3. Horm Res 45: 156-159, 1996.
142. Lalou C, Lassarre C, Binoux M. A proteolytic fragment of insulin-like growth factor (IGF) binding protein-3 that fails to bind IGF is a cell growth inhibitor. Prog Growth Factor Res 6: 311-316, 1995.
143. Lalou C, Lassarre C, Binoux M. A proteolytic fragment of insulin-like growth factor (IGF) binding protein-3 that fails to bind IGFs inhibits the mitogenic effects of IGF-I and insulin. Endocrinology 137: 3206-3212, 1996.
144. Laron Z, Klinger B, Blum WF, Silbergeld A, Ranke MB. IGF binding protein 3 in patients with Laron type dwarfism: effect of exogenous rIGF-I. Clin Endocrinol (Oxf) 36: 301-304, 1992.
145. Leahy JL, Vandekerkhove KM. Insulin-like growth factor-I at physiological concentrations is a potent inhibitor of insulin secretion. Endocrinology 126: 1593-1598, 1990.
146. Leal SM, Liu Q, Huang SS, Huang JS. The type V transforming growth factor beta receptor is the putative insulin-like growth factor-binding protein 3 receptor. J Biol Chem 272: 20572-20576, 1997.
147. Lee C, Sutkowski DM, Sensibar JA, Zelner D, Kim I, Amsel I, Shaw N, Prins GS, Kozlowski JM. Regulation of proliferation and production of prostate-specific antigen in androgen-sensitive prostatic cancer cells, LNCaP, by dihydrotestosterone. Endocrinology 136: 796-803, 1995.
148. Lee KW, Cobb LJ, Paharkova-Vatchkova V, Liu B, Milbrandt J, Cohen P. Contribution of the orphan nuclear receptor Nur77 to the apoptotic action of IGFBP-3. Carcinogenesis 28: 1653-1658, 2007.
149. Lee KW, Liu B, Ma L, Li H, Bang P, Koeffler HP, Cohen P. Cellular internalization of insulin-like growth factor binding protein-3: distinct endocytic pathways facilitate re-uptake and nuclear localization. J Biol Chem 279: 469-476, 2004.
150. Lee KW, Ma L, Yan X, Liu B, Zhang XK, Cohen P. Rapid apoptosis induction by IGFBP-3 involves an insulin-like growth factor-independent nucleomitochondrial translocation of RXRalpha/Nur77. J Biol Chem 280: 16942-16948, 2005.
151. Lee SH, Takahashi M, Honke K, Miyoshi E, Osumi D, Sakiyama H, Ekuni A, Wang X, Inoue S, Gu J, Kadomatsu K, Taniguchi N. Loss of core fucosylation of low-density lipoprotein receptor-related protein-1 impairs its function, leading to the upregulation of serum levels of insulin-like growth factor-binding protein 3 in Fut8-/- mice. J Biochem 139: 391-398, 2006.
152. Lelbach A, Scharf JG, Ramadori G. Regulation of insulin-like growth factor-I and of insulin-like growth factor binding protein-1, -3 and -4 in cocultures of rat hepatocytes and Kupffer cells by interleukin-6. J Hepatol 35: 558-567, 2001.
153. Lemmey AB, Glassford J, Flick-Smith HC, Holly JM, Pell JM. Differential regulation of tissue insulin-like growth factor-binding protein (IGFBP)-3, IGF-I and IGF type 1 receptor mRNA levels, and serum IGF-I and IGFBP concentrations by growth hormone and IGF-I. J Endocrinol 154: 319-328, 1997.
154. LeRoith D, Roberts CT Jr. The insulin-like growth factor system and cancer. Cancer Lett 195: 127-137, 2003.
155. Li Q, Li B, Wang X, Leri A, Jana KP, Liu Y, Kajstura J, Baserga R, Anversa P. Overexpression of insulin-like growth factor-1 in mice protects from myocyte death after infarction, attenuating ventricular dilation, wall stress, and cardiac hypertrophy. J Clin Invest 100: 1991- 1999, 1997.
156. Li W, Fawcett J, Widmer HR, Fielder PJ, Rabkin R, Keller GA. Nuclear transport of insulin-like growth factor-I and insulin-like growth factor binding protein-3 in opossum kidney cells. Endocrinology 138: 1763-1766, 1997.
157. Li Y, Xiang J, Duan C. Insulin-like growth factor-binding protein-3 plays an important role in regulating pharyngeal skeleton and inner ear formation and differentiation. J Biol Chem 280: 3613-3620, 2005.
158. Liao L, Chen X, Wang S, Parlow AF, Xu J. Steroid receptor coactivator 3 maintains circulating insulin-like growth factor I (IGF-I) by controlling IGF-binding protein 3 expression. Mol Cell Biol 28: 2460-2469, 2008.
159. Liu B, Lee HY, Weinzimer SA, Powell DR, Clifford JL, Kurie JM, Cohen P. Direct functional interactions between insulin-like growth factor-binding protein-3 and retinoid X receptor-alpha regulate transcriptional signaling and apoptosis. J Biol Chem 275: 33607-33613, 2000.
160. Liu B, Lee KW, Anzo M, Zhang B, Zi X, Tao Y, Shiry L, Pollak M, Lin S, Cohen P. Insulin-like growth factor-binding protein-3 inhibition of prostate cancer growth involves suppression of angiogenesis. Oncogene 26: 1811-1819, 2007.
161. Liu B, Lee KW, Li H, Ma L, Lin GL, Chandraratna RA, Cohen P. Combination therapy of insulin-like growth factor binding protein-3 and retinoid X receptor ligands synergize on prostate cancer cell apoptosis in vitro and in vivo. Clin Cancer Res 11: 4851-4856, 2005.
162. Liu B, Weinzimer SA, Gibson TB, Mascarenhas D, Cohen P. Type Ialpha collagen is an IGFBP-3 binding protein. Growth Horm IGF Res 13: 89-97, 2003.
163. Lofqvist C, Chen J, Connor KM, Smith AC, Aderman CM, Liu N, Pintar JE, Ludwig T, Hellstrom A, Smith LE. IGFBP3 suppresses retinopathy through suppression of oxygen-induced vessel loss and promotion of vascular regrowth. Proc Natl Acad Sci USA 104: 10589-10594, 2007.
164. Loidl P, Loidl A, Puschendorf B, Grobner P. RNA polymerase activity and template activity of chromatin after butyrate induced hyperacetylation of histones in Physarum. Nucleic Acids Res 12: 5405-5417, 1984.
165. Lu XF, Jiang XG, Lu YB, Bai JH, Mao ZB. Characterization of a novel positive transcription regulatory element that differentially regulates the insulin-like growth factor binding protein-3 (IGFBP-3) gene in senescent cells. J Biol Chem 280: 22606-22615, 2005.
166. Mangasser-Stephan K, Gressner AM. Molecular and functional aspects of latent transforming growth factor-beta binding protein: just a masking protein? Cell Tissue Res 297: 363-370, 1999.
167. Mannhardt B, Weinzimer SA, Wagner M, Fiedler M, Cohen P, Jansen-Durr P, Zwerschke W. Human papillomavirus type 16 E7 oncoprotein binds and inactivates growth-inhibitory insulin-like growth factor binding protein 3. Mol Cell Biol 20: 6483-6495, 2000.
168. Martin JL, Baxter RC. Transforming growth factor-beta stimulates production of insulin-like growth factor-binding protein-3 by human skin fibroblasts. Endocrinology 128: 1425-1433, 1991.
169. Martin JL, Coverley JA, Pattison ST, Baxter RC. Insulin-like growth factor-binding protein-3 production by MCF-7 breast cancer cells: stimulation by retinoic acid and cyclic adenosine monophosphate and differential effects of estradiol. Endocrinology 136: 1219-1226, 1995.
170. Martin JL, Pattison SL. Insulin-like growth factor binding protein-3 is regulated by dihydrotestosterone and stimulates deoxyribonucleic acid synthesis and cell proliferation in LNCaP prostate carcinoma cells. Endocrinology 141: 2401-2409, 2000.
171. McCaig C, Perks CM, Holly JM. Intrinsic actions of IGFBP-3 and IGFBP-5 on Hs578T breast cancer epithelial cells: inhibition or accentuation of attachment and survival is dependent upon the presence of fibronectin. J Cell Sci 115: 4293-4303, 2002.
172. McCusker RH, Camacho-Hubner C, Bayne ML, Cascieri MA, Clemmons DR. Insulin-like growth factor (IGF) binding to human fibroblast and glioblastoma cells: the modulating effect of cell released IGF binding proteins (IGFBPs). J Cell Physiol 144: 244-253, 1990.
173. Megyesi K, Kahn CR, Roth J, Gorden P. Circulating NSILA-s in man: Preliminary studies of stimuli in vivo and of binding to plasma components. J Clin Endocrinol Metab 41: 475-484, 1975.
174. Meuli C, Zapf J, Froesch ER. NSILA-carrier protein abolishes the action of nonsuppressible insulin-like activity (NSILA-S) on perfused rat heart. Diabetologia 14: 255-259, 1978.
175. Miller BS, Khosravi MJ, Patterson MC, Conover CA. The insulin-like growth factor system in children with congenital disorders of glycosylation. Clin Endocrinol (Oxf), 2009.
176. Mishra S, Raz A, Murphy LJ. Insulin-like growth factor binding protein-3 interacts with autocrine motility factor/phosphoglucose isomerase (AMF/PGI) and inhibits the AMF/PGI function. Cancer Res 64: 2516-2522, 2004.
177. Modric T, Silha JV, Shi Z, Gui Y, Suwanichkul A, Durham SK, Powell DR, Murphy LJ. Phenotypic manifestations of insulin-like growth factor-binding protein-3 overexpression in transgenic mice. Endocrinology 142: 1958-1967, 2001.
178. Murphy LJ, Molnar P, Lu X, Huang H. Expression of human insulinlike growth factor-binding protein-3 in transgenic mice. J Mol Endocrinol 15: 293-303, 1995.
179. Murphy LJ, Rajkumar K, Molnar P. Phenotypic manifestations of insulin-like growth factor binding protein-1 (IGFBP-1) and IGFBP-3 overexpression in transgenic mice. Prog Growth Factor Res 6: 425-432, 1995.
180. Muzumdar RH, Ma X, Fishman S, Yang X, Atzmon G, Vuguin P, Einstein FH, Hwang D, Cohen P, Barzilai N. Central and opposing effects of IGF-I and IGF-binding protein-3 on systemic insulin action. Diabetes 55: 2788-2796, 2006.
181. Nickerson T, Huynh H. Vitamin D analogue EB1089-induced prostate regression is associated with increased gene expression of insulin-like growth factor binding proteins. J Endocrinol 160: 223-229, 1999.
182. Ning Y, Schuller AG, Bradshaw S, Rotwein P, Ludwig T, Frystyk J, Pintar JE. Diminished growth and enhanced glucose metabolism in triple knockout mice containing mutations of insulin-like growth factor binding protein-3, -4, and -5. Mol Endocrinol 20: 2173-2186, 2006.
183. Oh Y, Gucev Z, Ng L, Muller HL, Rosenfeld RG. Antiproliferative actions of insulin-like growth factor binding protein (IGFBP)-3 in human breast cancer cells. Prog Growth Factor Res 6: 503-512, 1995.
184. Oh Y, Muller HL, Lamson G, Rosenfeld RG. Insulin-like growth factor (IGF)-independent action of IGF-binding protein-3 in Hs578T human breast cancer cells. Cell surface binding and growth inhibition. J Biol Chem 268: 14964-14971, 1993.
185. Oh Y, Muller HL, Ng L, Rosenfeld RG. Transforming growth factor-beta-induced cell growth inhibition in human breast cancer cells is mediated through insulin-like growth factor-binding protein-3 action. J Biol Chem 270: 13589-13592, 1995.
186. Oh Y, Muller HL, Pham H, Rosenfeld RG. Demonstration of receptors for insulin-like growth factor binding protein-3 on Hs578T human breast cancer cells. J Biol Chem 268: 26045-26048, 1993.
187. Ongeri EM, Verderame MF, Hammond JM. The TATA binding protein associated factor 4b (TAF4b) mediates FSH stimulation of the IGFBP-3 promoter in cultured porcine ovarian granulosa cells. Mol Cell Endocrinol 278: 29-35, 2007.
188. Oufattole M, Lin SW, Liu B, Mascarenhas D, Cohen P, Rodgers BD. Ribonucleic acid polymerase II binding subunit 3 (Rpb3), a potential nuclear target of insulin-like growth factor binding protein-3. Endocrinology 147: 2138-2146, 2006.
189. Pagano M, Benmaamar R. When protein destruction runs amok, malignancy is on the loose. Cancer Cell 4: 251-256, 2003.
190. Park R, Shepherd BS, Nishioka RS, Grau EG, Bern HA. Effects of homologous pituitary hormone treatment on serum insulin-like growth-factor- binding proteins (IGFBPs) in hypophysectomized tilapia, Oreochromis mossambicus, with special reference to a novel 20-kDa IGFBP. Gen Comp Endocrinol 117: 404-412, 2000.
191. Parker MI, de Haan JB, Gevers W. DNA hypermethylation in sodium butyrate-treated WI-38 fibroblasts. J Biol Chem 261: 2786-2790, 1986.
192. Peng L, Malloy PJ, Feldman D. Identification of a functional vitamin D response element in the human insulin-like growth factor binding protein- 3 promoter. Mol Endocrinol 18: 1109-1119, 2004.
193. Peng L, Malloy PJ, Wang J, Feldman D. Growth inhibitory concentrations of androgens up-regulate insulin-like growth factor binding protein-3 expression via an androgen response element in LNCaP human prostate cancer cells. Endocrinology 147: 4599-4607, 2006.
194. Pratt SE, Pollak MN. Estrogen and antiestrogen modulation of MCF7 human breast cancer cell proliferation is associated with specific alterations in accumulation of insulin-like growth factor-binding proteins in conditioned media. Cancer Res 53: 5193-5198, 1993.
195. Radulescu RT. Nuclear localization signal in insulin-like growth factor-binding protein type 3. Trends Biochem Sci 19: 278, 1994.
196. Rajah R, Lee KW, Cohen P. Insulin-like growth factor binding protein- 3 mediates tumor necrosis factor-alpha-induced apoptosis: role of Bcl-2 phosphorylation. Cell Growth Differ 13: 163-171, 2002.
197. Rajah R, Valentinis B, Cohen P. Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-beta1 on programmed cell death through a p53- and IGF-independent mechanism. J Biol Chem 272: 12181-12188, 1997.
198. Rehault S, Monget P, Mazerbourg S, Tremblay R, Gutman N, Gauthier F, Moreau T. Insulin-like growth factor binding proteins (IGFBPs) as potential physiological substrates for human kallikreins hK2 and hK3. Eur J Biochem 268: 2960-2968, 2001.
199. Renehan AG, Zwahlen M, Minder C, O'Dwyer ST, Shalet SM, Egger M. Insulin-like growth factor (IGF)-I, IGF binding protein-3, and cancer risk: systematic review and meta-regression analysis. Lancet 363: 1346-1353, 2004.
200. Ricort JM, Binoux M. Insulin-like growth factor-binding protein-3 activates a phosphotyrosine phosphatase. Effects on the insulin-like growth factor signaling pathway. J Biol Chem 277: 19448-19454, 2002.
201. Ricort JM, Lombet A, Lassarre C, Binoux M. Insulin-like growth factor binding protein-3 increases intracellular calcium concentrations in MCF-7 breast carcinoma cells. FEBS Lett 527: 293-297, 2002.
202. Riggs MG, Whittaker RG, Neumann JR, Ingram VM. n-Butyrate causes histone modification in HeLa and Friend erythroleukaemia cells. Nature 268: 462-464, 1977.
203. Rinderknecht E, Humbel RE. The amino acid sequence of human insulin-like growth factor I and its structural homology with proinsulin. J Biol Chem 253: 2769-2776, 1978.
204. Roddam AW, Allen NE, Appleby P, Key TJ, Ferrucci L, Carter HB, Metter EJ, Chen C, Weiss NS, Fitzpatrick A, Hsing AW, Lacey JV Jr, Helzlsouer K, Rinaldi S, Riboli E, Kaaks R, Janssen JA, Wildhagen MF, Schroder FH, Platz EA, Pollak M, Giovannucci E, Schaefer C, Quesenberry CP Jr, Vogelman JH, Severi G, English DR, Giles GG, Stattin P, Hallmans G, Johansson M, Chan JM, Gann P, Oliver SE, Holly JM, Donovan J, Meyer F, Bairati I, Galan P. Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies. Ann Intern Med 149: 461-471, W483-468, 2008.
205. Rothberg KG, Heuser JE, Donzell WC, Ying YS, Glenney JR, Anderson RG. Caveolin, a protein component of caveolae membrane coats. Cell 68: 673-682, 1992.
206. Rozen F, Zhang J, Pollak M. Antiproliferative action of tumor necrosis factor-alpha on MCF-7 breastcancer cells is associated with increased insulin-like growth factor binding protein-3 accumulation. Int J Oncol 13: 865-869, 1998.
207. Santer FR, Bacher N, Moser B, Morandell D, Ressler S, Firth SM, Spoden GA, Sergi C, Baxter RC, Jansen-Durr P, Zwerschke W. Nuclear insulin-like growth factor binding protein-3 induces apoptosis and is targeted to ubiquitin/proteasome-dependent proteolysis. Cancer Res 66: 3024-3033, 2006.
208. Santer FR, Moser B, Spoden GA, Jansen-Durr P, Zwerschke W. Human papillomavirus type 16 E7 oncoprotein inhibits apoptosis mediated by nuclear insulin-like growth factor-binding protein-3 by enhancing its ubiquitin/proteasome-dependent degradation. Carcinogenesis 28: 2511-2520, 2007.
209. Schedlich LJ, Graham LD, O'Han MK, Muthukaruppan A, Yan X, Firth SM, Baxter RC. Molecular basis of the interaction between IGFBP-3 and retinoid X receptor: role in modulation of RAR-signaling. Arch Biochem Biophys 465: 359-369, 2007.
210. Schedlich LJ, Le Page SL, Firth SM, Briggs LJ, Jans DA, Baxter RC. Nuclear import of insulin-like growth factor-binding protein-3 and -5 is mediated by the importin beta subunit. J Biol Chem 275: 23462-23470, 2000.
211. Schedlich LJ, Nilsen T, John AP, Jans DA, Baxter RC. Phosphorylation of insulin-like growth factor binding protein-3 by deoxyribonucleic acid-dependent protein kinase reduces ligand binding and enhances nuclear accumulation. Endocrinology 144: 1984-1993, 2003.
212. Schedlich LJ, O'Han MK, Leong GM, Baxter RC. Insulin-like growth factor binding protein-3 prevents retinoid receptor heterodimerization: implications for retinoic acid-sensitivity in human breast cancer cells. Biochem Biophys Res Commun 314: 83-88, 2004.
213. Schedlich LJ, Young TF, Firth SM, Baxter RC. Insulin-like growth factor-binding protein (IGFBP)-3 and IGFBP-5 share a common nuclear transport pathway in T47D human breast carcinoma cells. J Biol Chem 273: 18347-18352, 1998.
214. Schwarze SR, DePrimo SE, Grabert LM, Fu VX, Brooks JD, Jarrard DF. Novel pathways associated with bypassing cellular senescence in human prostate epithelial cells. J Biol Chem 277: 14877-14883, 2002.
215. Shang Y, Baumrucker CR, Green MH. Signal relay by retinoic acid receptors alpha and beta in the retinoic acid-induced expression of insulin-like growth factor-binding protein-3 in breast cancer cells. J Biol Chem 274: 18005-18010, 1999.
216. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, Campos D, Maoleekoonpiroj S, Smylie M, Martins R, van Kooten M, Dediu M, Findlay B, Tu D, Johnston D, Bezjak A, Clark G, Santabarbara P, Seymour L. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353: 123-132, 2005.
217. Shim ML, Levitt Katz LE, Davis J, Dotzler WC, Cohen P, Ferry RJ Jr. Insulin-like growth factor binding protein-3 is a novel mediator of apoptosis in insulin-secreting cells. Growth Horm IGF Res 14: 216-225, 2004.
218. Shon JK, Shon BH, Park IY, Lee SU, Fa L, Chang KY, Shin JH, Lee YI. Hepatitis B virus-X protein recruits histone deacetylase 1 to repress insulin-like growth factor binding protein 3 transcription. Virus Res, 2008.
219. Shukla S, Mishra A, Fu P, MacLennan GT, Resnick MI, Gupta S. Up-regulation of insulin-like growth factor binding protein-3 by apigenin leads to growth inhibition and apoptosis of 22Rv1 xenograft in athymic nude mice. FASEB J 19: 2042-2044, 2005.
220. Silha JV, Gui Y, Mishra S, Leckstrom A, Cohen P, Murphy LJ. Overexpression of gly56/gly80/gly81-mutant insulin-like growth factorbinding protein-3 in transgenic mice. Endocrinology 146: 1523-1531, 2005.
221. Silha JV, Gui Y, Murphy LJ. Impaired glucose homeostasis in insulinlike growth factor-binding protein-3-transgenic mice. Am J Physiol Endocrinol Metab 283: E937-E945, 2002.
222. Silha JV, Sheppard PC, Mishra S, Gui Y, Schwartz J, Dodd JG, Murphy LJ. Insulin-like growth factor (IGF) binding protein-3 attenuates prostate tumor growth by IGF-dependent and IGF-independent mechanisms. Endocrinology 147: 2112-2121, 2006.
223. Singh B, Charkowicz D, Mascarenhas D. Insulin-like growth factor-independent effects mediated by a C-terminal metal-binding domain of insulin-like growth factor binding protein-3. J Biol Chem 279: 477-487, 2004.
224. Singh RP, Dhanalakshmi S, Tyagi AK, Chan DC, Agarwal C, Agarwal R. Dietary feeding of silibinin inhibits advance human prostate carcinoma growth in athymic nude mice and increases plasma insulinlike growth factor-binding protein-3 levels. Cancer Res 62: 3063-3069, 2002.
225. Sloth Andersen A, Hertz Hansen P, Schaffer L, Kristensen C. A new secreted insect protein belonging to the immunoglobulin superfamily binds insulin and related peptides and inhibits their activities. J Biol Chem 275: 16948-16953, 2000.
226. Smart EJ, Graf GA, McNiven MA, Sessa WC, Engelman JA, Scherer PE, Okamoto T, Lisanti MP. Caveolins, liquid-ordered domains, and signal transduction. Mol Cell Biol 19: 7289-7304, 1999.
227. Smith GC, Jackson SP. The DNA-dependent protein kinase. Genes Dev 13: 916-934, 1999.
228. Soh J, Katsuyama M, Ushijima S, Mizutani Y, Kawauchi A, Yabe- Nishimura C, Miki T. Localization of increased insulin-like growth factor binding protein-3 in diabetic rat penis: implications for erectile dysfunction. Urology 70: 1019-1023, 2007.
229. Solomon SS, Poffenbarger PL, Hepp DK, Fenster LF, Ensinck JW, Williams RH. Quantitation and partial characterization of nonsuppressible insulin-like activity in serum and tissue extracts of the rat. Endocrinology 81: 213-225, 1967.
230. Song H, Beattie J, Campbell IW, Allan GJ. Overlap of IGF- and heparin-binding sites in rat IGF-binding protein-5. J Mol Endocrinol 24: 43-51, 2000.
231. Sordella R, Bell DW, Haber DA, Settleman J. Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science 305: 1163-1167, 2004.
232. Spagnoli A, Torello M, Nagalla SR, Horton WA, Pattee P, Hwa V, Chiarelli F, Roberts CT Jr, and Rosenfeld RG. Identification of STAT-1 as a molecular target of IGFBP-3 in the process of chondrogenesis. J Biol Chem 277: 18860-18867, 2002.
233. Terashita K, Hashimoto Y, Niikura T, Tajima H, Yamagishi Y, Ishizaka M, Kawasumi M, Chiba T, Kanekura K, Yamada M, Nawa M, Kita Y, Aiso S, Nishimoto I. Two serine residues distinctly regulate the rescue function of Humanin, an inhibiting factor of Alzheimer's disease-related neurotoxicity: functional potentiation by isomerization and dimerization. J Neurochem 85: 1521-1538, 2003.
234. Tsubaki J, Hwa V, Twigg SM, Rosenfeld RG. Differential activation of the IGF binding protein-3 promoter by butyrate in prostate cancer cells. Endocrinology 143: 1778-1788, 2002.
235. Twigg SM, Kiefer MC, Zapf J, Baxter RC. Insulin-like growth factor-binding protein 5 complexes with the acid-labile subunit. Role of the carboxyl-terminal domain. J Biol Chem 273: 28791-28798, 1998.
236. Valentinis B, Bhala A, DeAngelis T, Baserga R, Cohen P. The human insulin-like growth factor (IGF) binding protein-3 inhibits the growth of fibroblasts with a targeted disruption of the IGF-I receptor gene. Mol Endocrinol 9: 361-367, 1995.
237. Vasylyeva TL, Chen X, Ferry RJ Jr. Insulin-like growth factor binding protein-3 mediates cytokine-induced mesangial cell apoptosis. Growth Horm IGF Res 15: 207-214, 2005.
238. Velayudhan BT, Govoni KE, Hoagland TA, Zinn SA. Growth rate and changes of the somatotropic axis in beef cattle administered exogenous bovine somatotropin beginning at two hundred, two hundred fifty, and three hundred days of age. J Anim Sci 85: 2866-2872, 2007.
239. Verrijdt G, Haelens A, Claessens F. Selective DNA recognition by the androgen receptor as a mechanism for hormone-specific regulation of gene expression. Mol Genet Metab 78: 175-185, 2003.
240. Vijayababu MR, Arunkumar A, Kanagaraj P, Arunakaran J. Effects of quercetin on insulin-like growth factors (IGFs) and their binding protein-3 (IGFBP-3) secretion and induction of apoptosis in human prostate cancer cells. J Carcinog 5: 10, 2006.
241. Vorwerk P, Yamanaka Y, Spagnoli A, Oh Y, Rosenfeld RG. Insulin and IGF binding by IGFBP-3 fragments derived from proteolysis, baculovirus expression and normal human urine. J Clin Endocrinol Metab 83: 1392-1395, 1998.
242. Walker GE, Wilson EM, Powell D, Oh Y. Butyrate, a histone deacetylase inhibitor, activates the human IGF binding protein-3 promoter in breast cancer cells: molecular mechanism involves an Sp1/Sp3 multiprotein complex. Endocrinology 142: 3817-3827, 2001.
243. Wang D, Nagpal ML, Shimasaki S, Ling N, Lin T. Interleukin-1 induces insulin-like growth factor binding protein-3 gene expression and protein production by Leydig cells. Endocrinology 136: 4049-4055, 1995.
244. Weinzimer SA, Gibson TB, Collett-Solberg PF, Khare A, Liu B, Cohen P. Transferrin is an insulin-like growth factor-binding protein-3 binding protein. J Clin Endocrinol Metab 86: 1806-1813, 2001.
245. Wiley A, Katsaros D, Chen H, Rigault de la Longrais IA, Beeghly A, Puopolo M, Singal R, Zhang Y, Amoako A, Zelterman D, Yu H. Aberrant promoter methylation of multiple genes in malignant ovarian tumors and in ovarian tumors with low malignant potential. Cancer 107: 299-308, 2006.
246. Wilson AJ, Arango D, Mariadason JM, Heerdt BG, Augenlicht LH. TR3/Nur77 in colon cancer cell apoptosis. Cancer Res 63: 5401-5407, 2003.
247. Wood WI, Cachianes G, Henzel WJ, Winslow GA, Spencer SA, Hellmiss R, Martin JL, Baxter RC. Cloning and expression of the growth hormone-dependent insulin-like growth factor-binding protein. Mol Endocrinol 2: 1176-1185, 1988.
248. Wraight CJ, Liepe IJ, White PJ, Hibbs AR, Werther GA. Intranuclear localization of insulin-like growth factor binding protein-3 (IGFBP-3) during cell division in human keratinocytes. J Invest Dermatol 111: 239-242, 1998.
249. Wraight CJ, Werther GA. Insulin-like growth factor-I and epidermal growth factor regulate insulin-like growth factor binding protein- 3 (IGFBP-3) in the human keratinocyte cell line HaCaT. J Invest Dermatol 105: 602-607, 1995.
250. Wu C, Yao G, Zou M, Chen G, Wang M, Liu J, Wang J, Xu D. N-Acetylgalactosaminyltransferase 14, a novel insulin-like growth factor binding protein-3 binding partner. Biochem Biophys Res Commun 357: 360-365, 2007.
251. Xiao CY, Hubner S, Jans DA. SV40 large tumor antigen nuclear import is regulated by the double-stranded DNA-dependent protein kinase site (serine 120) flanking the nuclear localization sequence. J Biol Chem 272: 22191-22198, 1997.
252. Xu S, Cwyfan-Hughes SC, van der Stappen JW, Sansom J, Burton JL, Donnelly M, Holly JM. Insulin-like growth factors (IGFs) and IGF-binding proteins in human skin interstitial fluid. J Clin Endocrinol Metab 80: 2940-2945, 1995.
253. Yakar S, Rosen CJ, Bouxsein ML, Sun H, Mejia W, Kawashima Y, Wu Y, Emerton K, Williams V, Jepsen K, Schaffler MB, Majeska RJ, Gavrilova O, Gutierrez M, Hwang D, Pennisi P, Frystyk J, Boisclair Y, Pintar J, Jasper H, Domene H, Cohen P, Clemmons D, Leroith D. Serum complexes of insulin-like growth factor-1 modulate skeletal integrity and carbohydrate metabolism. FASEB J, 2008.
254. Yamamoto H, Murphy LJ. Enzymatic conversion of IGF-I to des(1-3)IGF-I in rat serum and tissues: a further potential site of growth hormone regulation of IGF-I action. J Endocrinol 146: 141-148, 1995.
255. Yamamoto H, Murphy LJ. Generation of des-(1-3) insulin-like growth factor-I in serum by an acid protease. Endocrinology 135: 2432-2439, 1994.
256. Yamanaka Y, Fowlkes JL, Wilson EM, Rosenfeld RG, Oh Y. Characterization of insulin-like growth factor binding protein-3 (IGFBP-3) binding to human breast cancer cells: kinetics of IGFBP-3 binding and identification of receptor binding domain on the IGFBP-3 molecule. Endocrinology 140: 1319-1328, 1999.
257. Yan X, Forbes BE, McNeil KA, Baxter RC, Firth SM. Role of N- and C-terminal residues of insulin-like growth factor (IGF)-binding protein-3 in regulating IGF complex formation and receptor activation. J Biol Chem 279: 53232-53240, 2004.
258. Yandell CA, Francis GL, Wheldrake JF, Upton Z. Kangaroo IGF-II is structurally and functionally similar to the human [Ser29]-IGF-II variant. J Endocrinol 161: 445-453, 1999.
259. Zapf J, Hauri C, Waldvogel M, Futo E, Hasler H, Binz K, Guler HP, Schmid C, Froesch ER. Recombinant human insulin-like growth factor I induces its own specific carrier protein in hypophysectomized and diabetic rats. Proc Natl Acad Sci USA 86: 3813-3817, 1989.
260. Zhang Y, Dawson MI, Mohammad R, Rishi AK, Farhana L, Feng KC, Leid M, Peterson V, Zhang XK, Edelstein M, Eilander D, Biggar S, Wall N, Reichert U, Fontana JA. Induction of apoptosis of human B-CLL and ALL cells by a novel retinoid and its nonretinoidal analog. Blood 100: 2917-2925, 2002.
261. Zhao Y, Yin P, Bach LA, Duan C. Several acidic amino acids in the N-domain of insulin-like growth factor-binding protein-5 are important for its transactivation activity. J Biol Chem 281: 14184-14191, 2006.
262. Zhou Y, Mohan S, Linkhart TA, Baylink DJ, Strong DD. Retinoic acid regulates insulin-like growth factor-binding protein expression in human osteoblast cells. Endocrinology 137: 975-983, 1996.
263. Zhu J, Zhou W, Jiang J, Chen X. Identification of a novel p53 functional domain that is necessary for mediating apoptosis. J Biol Chem 273: 13030-13036, 1998.
264. Zimmermann EM, Li L, Hoyt EC, Pucilowska JB, Lichtman S, Lund PK. Cell-specific localization of insulin-like growth factor binding protein mRNAs in rat liver. Am J Physiol Gastrointest Liver Physiol 278: G447-G457, 2000.
265. Zingg AE, Froesch ER. Effects of partially purified preparations with nonsuppressible insulin-like activity (NSILA-S) on sulfate incorporation into rat and chicken cartilage. Diabetologia 9: 472-476, 1973.